A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma.
Eighteen untreated elderly patients (median age 75 years) with non-Hodgkin's lymphoma (NHL) entered a phase II study with oral Idarubicin (4-demethoxidaunorubicin) at a dosage of 30-35 mg/m2 on day 1 and every 3 weeks thereafter. The medium number of cycles administered was three (range one to nine). We obtained one (6%) complete response and four (25%) partial responses in 16 evaluable patients. Toxicity was mild and no cardiotoxicity was found. At this dosage Idarubicin showed little anticancer activity in NHL.
Errante
D
D
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Sorio
R
R
Zagonel
V
V
Carbone
A
A
Monfardini
S
S
Tirelli
U
U
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D012074:Remission Induction
D015255:Idarubicin